PERCEPTIVE ADVISORS LLC
Q3 2021 13F-HR/A Holdings
Net value change ($000)
-806,469
(-10.5%)
New positions
21
Sold out positions
31
Turnover %
13.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IVERIC bio, Inc. | 92,407 | 319.4% |
| Mirati Therapeutics, Inc. | 84,708 | 16.5% |
| PRCT | 63,214 | NEW |
| Icosavax, Inc. | 56,888 | NEW |
| Landos Biopharma, Inc. | 45,354 | 26.4% |
| Cerevel Therapeutics Holdings, Inc. | 31,102 | 26.1% |
| FOLD | 30,753 | 13.8% |
| AVIR | 30,680 | 63.2% |
| Horizon Therapeutics Public Ltd Co | 28,488 | 15.3% |
| SomaLogic, Inc. | 25,400 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| BBIO | -109,295 | -23.1% |
| NEVRO CORP | -105,486 | -77.7% |
| SpringWorks Therapeutics, Inc. | -92,003 | -23.0% |
| UTHR | -84,505 | -76.4% |
| Kadmon Holdings, Inc. | -60,803 | -100.0% |
| MDT | -55,858 | -100.0% |
| Zymergen Inc. | -53,716 | -82.2% |
| RCKT | -52,814 | -43.3% |
| Invitae Corp | -50,987 | -31.4% |
| Singular Genomics Systems, Inc. | -50,321 | -59.4% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
21,994
(0.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|